Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Top 13 HIV and Hepatitis Stories of 2013

In our last issue for 2013, HIVandHepatitis.com reviews some the year's major HIV, viral hepatitis, and related news highlights, including the advent of effective new therapies for hepatitis C, new global guidelines recommending earlier HIV treatment, and mixed results in the HIV cure field.

alt

Read more:

Happy Holidays from HIVandHepatitis.com

alt

BMS Licenses Atazanavir to Medicines Patent Pool, Allowing Cheaper Generics

Bristol-Myers Squibb and the Medicines Patent Pool have reached a licensing agreement that will enable generic drug manufacturers to produce inexpensive versions of the HIV protease inhibitor atazanavir (Reyataz), as well as fixed-dose combinations containing the drug, for use in low-income countries, MPP recently announced. It is the first MPP agreement to cover a preferred second-line therapy.

alt

Read more:

FDA Approves Complera as Switch Option for People with Suppressed HIV

The U.S. Food and Drug Administration this month expanded the indication for the single-tablet regimen Complera (rilpivirine/tenofovir/emtricitabine, known as Eviplera in Europe). The 3-in-1 combination pill is now approved for people with suppressed viral load who wish to switch regimens.

alt

Read more:

IDSA Issues New Guidelines for Vaccination of Immune-compromised People

The Infectious Diseases Society of America (IDSA) this month released new recommendations for vaccinations for people with HIV and other immune-compromising conditions. The guidelines were published in the December 4, 2013, advance edition of Clinical Infectious Diseases.

alt

Read more:

FDA Approves Complera as Switch Option for People with Suppressed HIV

TEXT

alt

Read more:

Conditioning with Cytoxan Increases Protected Cells in HIV Gene Therapy Trial

Administering cyclophosphamide (Cytoxan), a chemotherapy drug toxic to certain immune cells, prior to zinc-finger gene therapy appears to make room for increased proliferation of altered CD4 T-cells lacking the CCR5 co-receptor, researchers reported at the 6th International Workshop on HIV Persistence during Therapy last week in Miami.

alt

Read more: